The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SVRA | +31.08% | +309.62% | +32.56% | -51% |
| S&P | +14.49% | +91.09% | +13.83% | +187% |
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Austin, TX.
The company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy.
The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.08M | -10.1% |
| Market Cap | $617.03M | -11.6% |
| Market Cap / Employee | $10.46M | 0.0% |
| Employees | 59 | 59.5% |
| Net Income | -$29.56M | -21.9% |
| EBITDA | -$30.18M | -14.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $16.28M | -24.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $29.78M | 12.2% |
| Short Term Debt | $0.05M | -68.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -60.91% | -21.5% |
| Return On Invested Capital | -38.32% | 2.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$22.53M | 0.6% |
| Operating Free Cash Flow | -$22.53M | 0.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.63 | 2.79 | 2.66 | 5.12 | 40.94% |
| Price to Tangible Book Value | 2.79 | 2.96 | 2.87 | 5.67 | 47.30% |
| Enterprise Value to EBITDA | -22.68 | -17.34 | -14.53 | -12.48 | -48.80% |
| Return on Equity | -61.5% | -75.8% | -99.3% | -78.7% | 64.20% |
| Total Debt | $26.82M | $29.65M | $29.74M | $29.83M | 11.69% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
